DOP29: A novel predictive scoring system of venous thromboembolism after surgery for Inflammatory Bowel Disease: A NSQIP-IBD registry analysisECCO'22Year: 2022
Authors: Cheong, J.Y.(1);Connelly, T.(1);Prien, C.(1);Jia, X.(1);Valente, M.(1);Bhama, A.(1);Lightner, A.(1);HolubarMD- MS, S.(1);
(1)Cleveland Clinic, Department of Colon & Rectal Surgery, Cleveland, United States;
DOP30: Long-term outcomes of Crohn’s perianal fistulas treatment: anti-TNF with surgical closure versus anti-TNF alone (PISA-II) - A patient preference RCTECCO'22Year: 2022
Authors: Meima - van PraagMD, E.(1);Stoker, J.(2);D'Haens, G.(3);Gecse, K.(4);Dijkgraaf, M.(5);Bemelman, W.(1);Buskens, C.(1);
(1)Amsterdam UMC, Surgery, Amsterdam, The Netherlands;(2)Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC, Gastroenterology and Hepatology, Gastroenterology and Hepatology, The Netherlands;(4)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)Amsterdam UMC, Clinical Epidemiology- Biostatistics and Bioinformatics, Amsterdam, The Netherlands;
DOP31: Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianal fistulae in Crohn’s Disease: Results from a prospective monocentric studyECCO'22Year: 2022
Authors: Reenaers Dr, C.(1);Vieujean , S.(1);Coimbra , C.(2);Gillard , R.(3);Meunier , P.(3);Boutaffala , L.(1);Louis , E.(1);
(1)CHU Liège- Sart Tilman, Department of Gastroenterology, Liège, Belgium;(2)CHU Liège- Sart Tilman, Department of abdominal surgery, Liège, Belgium;(3)CHU Liège- Sart Tilman, Department of radiology, Liège, Belgium;
DOP33: Role of adherent and invasive E. coli in Crohn’s Disease: Lessons from the postoperative recurrence modelECCO'22Year: 2022
Authors: Buisson, A.(1);Sokol, H.(2);Hammoudi, N.(3);Nancey, S.(4);Treton, X.(5);Nachury, M.(6);Fumery, M.(7);Hébuterne, X.(8);Rodrigues, M.(9);Hugot, J.P.(10);Boschetti, G.(4);Stefanescu, C.(5);Wils , P.(6);Seksik, P.(2);Le Bourhis, L.(3);Bezault, M.(11);Sauvanet, P.(9);Pereira, B.(12);Allez, M.(3);Barnich, N.(9);
(1)University Hospital Estaing, Department of Gastroenterology- IBD Unit, Clermont-Ferrand, France;(2)AP-HP Saint-Antoine Hospital, IBD Unit, Paris, France;(3)AP-HP Saint-Louis Hospital, IBD Unit, Paris, France;(4)HCL-Lyon Sud, IBD Unit, Lyon, France;(5)AP-HP Beaujon Hospital, IBD Unit, Paris, France;(6)CHRU Lille, IBD Unit, Lille, France;(7)CHU Amiens, IBD Unit, Amiens, France;(8)CHU Nice, IBD Unit, Nice, France;(9)Université Clermont Auvergne, M2iSH, Clermont--Ferrand, France;(10)Centre de recherche sur l’inflammation- INSERM UMR 1149- Assistance Publique-Hôpitaux de Paris- Université de Paris, IBD Unit, Paris, France;(11)REMIND group, Administrative staff, Paris, France;(12)University Hospital Estaing, DRCI- Statistics Unit, Clermont-Ferrand, France;REMIND study group
DOP34: Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn's Disease for modified Rutgeerts' score i2a and i2b categories: Individual patient data meta-analysisECCO'22Year: 2022
Authors: Riviere, P.(1);Pekow, J.(2);Hammoudi, N.(3);Wils, P.(4);De Cruz, P.(5);Wang, C.(6);Mañosa, M.(7);Ollech, J.(2);Allez, M.(3);Nachury, M.(4);Kamm, M.(5);Maya, A.(2);Ferrante, M.(8);Buisson, A.(9);Singh, S.(10);Laharie, D.(1);Momar, D.(11);Fumery, M.(12);
(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)University of Chicago, Gastroenterology, Chicago, United States;(3)Hôpital Saint-Louis, Gastroenterology, Paris, France;(4)Lille University Hospital, Gastroenterology, Lille, France;(5)The Austin Hospital, Gastroenterology, Melbourne, Australia;(6)Mount Sinai Hospital, Gastroenterology, New York, United States;(7)Hospital Germans Trias, Gastroenterology, Badalona, Spain;(8)Leuven University Hospitals, Gastroenterology, Leuven, Belgium;(9)Clermont Ferrand University Hospitals, Gastroenterology, Clermont Ferrand, France;(10)UC San Diego Health, Gastroenterology, San Diego, United States;(11)Amiens University Hospitals, Statistics, Amiens, France;(12)Amiens University Hospitals, Gastroenterology, Amiens, France;
DOP35: Increasing incidence of pouchitis among patients undergoing ileal pouch-anal anastomosis between 1996 and 2018: A population-based Danish cohort studyECCO'22Year: 2022
Authors: Barnes, E.(1);Allin, K.(2);Iversen, A.(2);Herfarth, H.(1);Jess, T.(2);
(1)University of North Carolina at Chapel Hill, Division of Gastroenterology and Hepatology, Chapel Hill, United States;(2)Center for Molecular Prediction of Inflammatory Bowel Disease- Aalborg University, Department of Clinical Medicine, Copenhagen, Denmark;
DOP36: Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter studyECCO'22Year: 2022
Authors: Sallette, M.(1);Bouhnik, Y.(2);Nachury, M.(3);Bellanger, C.(4);Laharie, D.(5);Amiot, A.(6);Peyrin-Biroulet, L.(7);Roblin, X.(8);Altwegg, R.(9);Buisson, A.(10);Reenaers, C.(11);Bouguen, G.(12);Vuitton, L.(13);Bourreille, A.(14);Gilletta, C.(15);Serrero, M.(16);Hébuterne, X.(17);Filippi, J.(18); Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
(1)Archet 2 University Hospital, Gastroenterology, Nice, France;(2)Beaujon University Hospital, Gastroenterology, Paris, France;(3)Lille University Hospital, Gastroenterology, Lille, France;(4)Kremlin Bicêtre Hospital, Gastroenterology, Paris, France;(5)Haut Lévêque Hospital, Gastroenterology, Bordeaux, France;(6)Henri Mondor University Hospital, Gastroenterology, Paris, France;(7)Nancy University Hospital, Gastroenterology, Nancy, France;(8)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(9)Montpellier University Hospital, Gastroenterology, Montpellier, France;(10)Clermont-Ferrand University Hospital, Gastroenteroogy, Clermont-Ferrand, France;(11)Liège University Hospital, Gastroenterology, Liège, Belgium;(12)Rennes University Hospital, Gastroenterology, Rennes, France;(13)Besançon University Hospital, Gastroenterology, Besançon, France;(14)Nantes University Hospital, Gastroenteroogy, Nantes, France;(15)Toulouse University Hospital, Gastroenterology, Toulouse, France;(16)Nord University Hospital, Gastroenterology, Marseille, France;(17)Archet 2 University Hospital, Gastroenterology, Nice, France;(18)Archet 2 Unversity Hospital, Gastroenterology, Nice, France;
DOP37: Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studiesECCO'22Year: 2022
Authors: SCHREIBER, S.(1);Loftus Jr, E.V.(2);Maaser, C.(3);Danese, S.(4,5);Rudolph, C.(6);Jongen, R.(6);De Haas, A.(6);Oortwijn, A.(6);Vermeire, S.(7);
(1)Kiel University, Medicine I, Kiel, Germany;(2)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(3)Hospital Lüneburg, Outpatients Department of Gastroenterology, Lüneburg, Germany;(4)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)Vita-Salute, San Raffaele University, Milan, Italy;(6)Galapagos, Nv, Leiden, The Netherlands;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
DOP38: Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1ECCO'22Year: 2022
Authors: Vermeire, S.(1);Colombel, J.F.(2);Takeuchi, K.(3);Gao, X.(4);Panaccione, R.(5);Danese, S.(6);Dubinsky, M.(7);Schreiber, S.(8);Ilo, D.(9);Finney-Hayward, T.(9);Zhou, W.(9);Phillips, C.(9);Yao, X.(9);Zhou, Q.(9);Loftus, E.(10);
(1)University Hospital Leuven, none, Leuven, Belgium;(2)Icahn School of Medicine at Mount Sinai, none, New York City, United States;(3)Tsujinaka Hospital Kashiwanoha- Kashiwa, Division of Gastroenterology and Hepatology, Chiba, Japan;(4)The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(5)University of Calgary, Division of Gastroenterology and Hepatology, Alberta, Canada;(6)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Department of Gastroenterology and Endoscopy, Milan, Italy;(7)Icahn School of Medicine at Mt Sinai, Department of Pediatric Gastroenterology, New York, United States;(8)University Hospital Schleswig-Holstein, none, Kiel, Germany;(9)AbbVie- Inc, none, North Chicago, United States;(10)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP39: Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programmeECCO'22Year: 2022
Authors: Higgins, P.(1);Colombel, J.F.(2);Reguiero, M.(3);Parkes, G.(4);Ilo, D.(5);Philips, C.(5);Yao, X.(6);Cheng, E.(6);Schreiber, S.(7);
(1)University of Michigan, Department of Internal Medicine, Ann Arbor, United States;(2)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(3)Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States;(4)Royal London Hospital, Department of Gastroenterology, London, United Kingdom;(5)AbbVie Inc, Research and Development, North Chicago- Illinois, United States;(6)AbbVie Inc, Data & Statistical Sciences, North Chicago- Illinois, United States;(7)University Hospital Schleswig-Holstein, Department of Internal Medicine, Kiel, Germany;
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative ColitisECCO'22Year: 2022
Authors: Raine, T.(1);Ishiguro, Y.(2);Rubin, D.(3);Finney-Hayward, T.(4);Dapo, I.(5);Phillips, C.(5);Cheng, E.(6);Targownik, L.(7);Loftus- Jr., E.V.(8);
(1)Addenbrooke's Hospital- Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(2)Hirosaki General Medical Centre- National Hospital Organisation, Department of Clinical Research, Hirosaki, Japan;(3)The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)AbbVie Ltd., Gastroenterology, Maidenhead, United Kingdom;(5)AbbVie Ltd., Research and Development, North Chicago, United States;(6)AbbVie Ltd., Data & Statistical Science, North Chicago, United States;(7)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology and Hepatology, Toronto, Canada;(8)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP41: Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative ColitisECCO'22Year: 2022
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Klaff, J.(3);Ilo, D.(3);Yao, X.(4);Levy, G.(5);Higgins, P.D.R.(6);Loftus- Jr., E.V.(7);Panaccione, R.(8);
(1)University Hospital Leuven & KU Leuven, Gastroenterology & Hepatology, Leuven, Belgium;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)AbbVie Inc., Research and Development, North Chicago- Illinois, United States;(4)AbbVie Inc., Data & Statistical Sciences, North Chicago- Illinois, United States;(5)AbbVie Inc., Pharmacovigilance & Patient Safety, North Chicago- Illinois, United States;(6)University of Michigan, Department of Medicine- Division of Gastroenterology, Ann Arbor- Michigan, United States;(7)Mayo Clinic- College of Medicine, Division of Gastroenterology and Hepatology, Rochester- Minnesota, United States;(8)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary- Alberta, Canada;
DOP42: Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC studyECCO'22Year: 2022
Authors: Danese, S.(1);Panaccione, R.(2);D'Haens, G.(3);Peyrin-Biroulet, L.(4);Schreiber, S.(5);Kobayashi, T.(6);Gawdis-Wojnarska, B.(7);Korga, P.(8);Aguilar, H.(9);Sharkey, B.(10);Sreih, A.(11);Radosti, C.(10);Patel, A.(10);Canavan, J.(10);Rubin, D.(12);
(1)Humanitas Research Hospital, Inflammatory Bowel Diseases Center, Milan, Italy;(2)University of Calgary, Inflammatory Bowel Disease Clinic, Calgary- Alberta, Canada;(3)Amsterdam University Medical Centers, Inflammatory Bowel Disease Unit, Amsterdam, Netherlands Antilles;(4)Nancy University Hospital, Gastroenterology, Nancy, France;(5)University Hospital Schleswig-Holstein, Gastroenterology, Kiel, Germany;(6)Kitasato University Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;(7)Twoja Przychodnia-Szczecińskie Centrum Medyczne, Gastroenterology, Szczecin, Poland;(8)Centrum Medyczne KERmed, Gastroenterology, Bydgoszcz, Poland;(9)Louisiana Research Center, Gastroenterology, Shreveport, United States;(10)Bristol Myers Squibb, Division of Immunology and Fibrosis Development, Princeton, United States;(11)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(12)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
DOP43: Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True NorthECCO'22Year: 2022
Authors: Siegmund, B.(1);Axelrad, J.(2);Pondel, M.(3);Osterman, M.T.(3);Ahmad, H.A.(3);Memaj, A.(3);Regueiro, M.(4);Armuzzi, A.(5);Afzali, A.(6);
(1)Charité – Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany;(2)NYU Langone Health, Gastroenterology, New York, United States;(3)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(4)Cleveland Clinic, Gastroenterology, Cleveland, United States;(5)Fondazione Policlinico A. Gemelli IRCCS, Catholic University of Rome, Rome, Italy;(6)The Ohio State University, Wexner Medical Center, Columbus, United States;
DOP44: Long-term use of ozanimod in patients with moderately to severely active Ulcerative ColitisECCO'22Year: 2022
Authors: Danese, S.(1);Colombel, J.F.(2);Ponich, T.(3);Jovanovic, I.(4);Bossuyt, P.(5);Longman, R.(6);Alekseeva, O.(7);Petersen, A.(8);Chitkara, D.(8);Marta, C.(8);Charles, L.(8);Rubin, D.T.(9);Afzali, A.(10);Loftus, E.V.(11);Wolf, D.C.(12);
(1)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)Western University, Gastroenterology, London, Canada;(4)University Hospital Medical Centre Bezanijska Kosa, Gastroenterology, Belgrade, Serbia;(5)Imelda GI Clinical Research Center- Imelda General Hospital, Gastroenterology, Bonheiden, Belgium;(6)Jill Roberts Center for Inflammatory Bowel Disease- Weill Cornell Medicine, Gastroenterology, New York, United States;(7)Nizhny Novgorod Regional Clinical Hospital, Gastroenterology, Nizhny Novgorod, Russian Federation;(8)Bristol Myers Squibb, Department of Fibrosis and Immunology, Princeton, United States;(9)University of Chicago Medicine Inflammatory Bowel Disease Center, Inflammatory Bowel Disease Center, Chicago, United States;(10)The Ohio State University Wexner Medical Center, Gastroenterology, Columbus, United States;(11)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(12)Atlanta Gastroenterology Associates, Center for Crohn’s Disease & Ulcerative Colitis, Atlanta, United States;
DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosisECCO'22Year: 2022
Authors: Armuzzi, A.(1);Cross, R.K.(2);Lichtenstein, G.(3);Calkwood, J.(4);Pai, A.(5);Pondel, M.(5);Ahmad, H.A.(5);Charles, L.(5);Elegbe, A.(5);Petersen, A.(5);Sheffield, J.K.(5);Javed, A.(6);Hou, J.(7);Regueiro, M.(8);Wolf, D.C.(9);Long, M.(10);
(1)Fondazione Policlinico A. Gemelli IRCCS- Catholic University of Rome, Gastroenterology, Rome, Italy;(2)University of Maryland School of Medicine, Gastroenterology, Baltimore, United States;(3)University of Pennsylvania, Gastroenterology, Philadelphia, United States;(4)Minneapolis Clinic of Neurology, Neurology, Minneapolis, United States;(5)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(6)University of Chicago, Neurology, Chicago, United States;(7)Baylor College of Medicine, Gastroenterology, Houston, United States;(8)Cleveland Clinic, Gastroenterology, Cleveland, United States;(9)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, United States;(10)UNC Chapel Hill, Gastroenterology, Chapel Hill, United States;
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cellsECCO'22Year: 2022
Authors: Wottawa, F.(1);Becker, B.(2);Bakr, M.(1);Kugler, J.(1);Mayr, L.(3);Paludan, S.(4);Blumberg, R.(5);Kaser, A.(6);Adolph, T.(3);Schreiber, S.(7);Meiser, J.(2);Rosenstiel, P.(1);Aden, K.(7);
(1)University Medical Center Schleswig-Holstein Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(2)Luxembourg Institute of Health, Department of Oncology, Luxembourg, Luxembourg;(3)Medical University of Innsbruck, Department of Internal Medicine I- Gastroenterology- Hepatology- Metabolism & Endocrinology, Innsbruck, Austria;(4)Aarhus University, Department of Biomedicine, Aarhus, Denmark;(5)Brigham and Women’s Hospital- Harvard Medical School, Gastroenterology Division- Department of Medicine, Boston, United States;(6)Addenbrooke’s Hospital- University of Cambridge, Department of Medicine, Cambridge, United Kingdom;(7)University Medical Center Schleswig-Holstein Kiel, Department of Medicine I, Kiel, Germany;
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s DiseaseECCO'22Year: 2022
Authors: Pesesky, M.(1);Carty, C.L.(1);Singh, N.(2);Le Bourhis, L.(3);Rosati, E.(4);Bokemeyer, B.(5);Schreiber, S.(4);Görg, S.(6);Gittelman, R.M.(1);Dines, J.N.(2);Kaplan, I.M.(7);Zahid, H.J.(8);Baldo, L.(2);Snyder, T.M.(1);Robins, H.S.(1);Franke, A.(4);Allez, M.(3);
(1)Adaptive Biotechnologies, Innovation, Seattle, United States;(2)Adaptive Biotechnologies, Medical Affairs and Clinical Development, Seattle, United States;(3)Hôpital Saint-Louis, Hepato-Gastero-Enterologie, Paris, France;(4)Christian-Albrecht University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(5)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis, Minden, Germany;(6)University Hospital of Schleswig-Holstein, Institute for Transfusion Medicine, Kiel, Germany;(7)Adaptive Biotechnologies, Partnerships, Seattle, United States;(8)Microsoft Research, Immunomics, Redmond, United States;
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBDECCO'22Year: 2022
Authors: Hanna, J.(1);Beke, F.(2);O'Brien, L.(2);Kapeni, C.(2);Chen, H.C.(2);Carbonaro, V.(2);Kim, A.(3);Kishore, K.(2);Adolph, T.E.(4);Skjoedt, M.O.(5);Skjoedt, K.(6);de la Roche, M.(7);de la Roche, M.(2);
(1)University of Cambridge, Cancer Research UK - Cambridge Institute / School of Clinical Medicine, Cambridge, United Kingdom;(2)University of Cambridge, Cancer Research UK - Cambridge Institute, Cambridge, United Kingdom;(3)Washington University in St. Louis, Washington University School of Medicine, St. Louis, United States;(4)Medical University Innsbruck, Department of Internal Medicine I- Gastroenterology- Hepatology & Endocrinology, Innsbruck, Austria;(5)University of Copenhagen, Institute of Immunology and Microbiology, Copenhagen, Denmark;(6)University of Southern Denmark, Department of Cancer and Inflammation Research, Odense, Denmark;(7)University of Cambridge, Department of Biochemistry, Cambridge, United Kingdom;
